A vaccine for Lassa fever may be on the horizon, thanks to a new clinical trial jointly led by Elissa Malkin, DO, MPH, assistant research professor of medicine at the George Washington University School of Medicine and Health Sciences. With an award from trial sponsor IAVI, Malkin, along with collaborators from Brigham and Women’s Hospital in Boston, Redemption Hospital in Monrovia, Liberia, and East-West Medical Research Institute in Honolulu, Hawaii, will be testing IAVI’s experimental vaccine candidate called “rVSV∆G-LASV-GPC,” a recombinant vesicular stomatitis virus (rVSV) vector-based vaccine expressing a Lassa virus protein (LASV-GPC).
SMHS-Led Clinical Trial To Assess Immunogenicity and Safety of Lassa Fever Vaccine
Latest News
A protective HIV vaccine will need to induce broadly neutralizing antibodies (bnAbs) in humans, but priming rare bnAb precursor B cells has been challenging. This study provides proof-of-concept for Env trimer-based GT approaches to activate bnAb precursors and induce affinity maturation on the…
The GW VRU participated in IAVI-G002 as a clinical site for a phase 1 human clinical trial. This study evaluated the safety and immunogenicity of mRNA-encoded nanoparticles as priming immunogens and first-boosting immunogens (IAVI-G002).
The GW VRU is proud to announce our newest publication to describe the development of a new Na-GST-1/Alhydrogel hookworm vaccine. This study showed promising results and can be read at the link below: